Verve Therapeutics is a clinical-stage genetic medicines company dedicated to addressing the global health crisis of cardiovascular disease. With a unique approach that aims to shift treatment from ongoing management to curative single-course gene editing therapies, Verve is developing innovative solutions targeting genes linked to elevated low-density lipoprotein cholesterol (LDL-C). Their lead programs, VERVE-101, VERVE-102, and VERVE-201, focus on permanently disabling the PCSK9 and ANGPTL3 genes to treat conditions such as heterozygous familial hypercholesterolemia and refractory hypercholesterolemia. Headquartered in Boston, Massachusetts, Verve Therapeutics has garnered recognition for its workplace culture, being named a Top Place to Work by The Boston Globe. The company values collaboration, innovation, and a commitment to transforming the lives of patients through cutting-edge genetic medicine.